

NYC-WTC_000233539

In case of disparity between the guidelines and criterias provided and the official version, these are the valid one.

Please contact your project manager for additionnals informations.

Solids data is based on dry weight (unless otherwise specified).

L"ןAרןaן,ן,ןaןc"ןCerןfןcאtןeן Nןo:ן2ןJן0ן5ן7ן3ן
ןnןhןC"ןAרןaן,ן,ן

NYC-WTC 000233540

NYC 9/11 Public Portal Document

R02100400R02100400R02100400			R02100400R02100400		
Client ID:	01A	01A	Client ID:	02A	02A
Lab No.:	039046 02	039046 02	Lab No.:	039047 02	039047 02
Date Sampled:	02/10/09	02/10/09	Date Sampled:	02/10/09	02/10/09
Matrix:			Matrix:		

Component	RDL	Units	TEF	% of Isomer	RDL	Units	TEF
2,3,7,8-Cl4DBP	0.09	pg	1.6	0.16	0.33	pg	3.2
2,3,7,8-Cl4DBP	0.19	"	1.1	1.1	0.61	"	<0.61
1,2,3,7,8-Cl5DBP	0.21	"	1.2	0.062	1.00	"	<1.00
2,3,4,7,8-Cl5DBP	0.21	"	1.1	0.57	0.22	"	0.82
1,2,3,7,8-Cl5DBP	0.14	"	0.89	0.44	0.54	"	<0.54
1,2,3,4,7,8-Cl6DBP	0.59	"	1.9	0.19	0.60	"	<0.60
1,2,3,6,7,8-Cl6DBP	0.22	"	<2.2	<0.22	0.63	"	<0.63
2,3,4,6,7,8-Cl6DBP	0.37	"	6.3	0.63	0.67	"	0.96
1,2,3,7,8,9-Cl6DBP	0.44	"	5.8	0.58	0.99	"	<0.99
1,2,3,4,7,8-Cl6DBP	0.30	"	<1.3	<0.13	0.41	"	<0.41
1,2,3,6,7,8-Cl6DBP	0.25	"	1.8	0.18	0.39	"	<0.39
1,2,3,7,8,9-Cl6DBP	0.35	"	2.6	0.26	1.4	"	<1.4
1,2,3,4,6,7,8-Cl7DBP	0.77	"	<4.8	<0.048	8.0	"	<8.0
1,2,3,4,7,8,9-Cl7DBP	0.77	"	6.4	0.064	2.1	"	<2.1
1,2,3,4,6,7,8-Cl7DBP	0.20	"	<2.5	<0.025	0.87	"	1.9
1,2,3,4,6,7,8,9-Cl8DBP	0.20	"	5.7	0.0057	0.5	"	11
1,2,3,4,6,7,8,9-Cl8DBP	0.20	"	9.3	0.0093	0.63	"	9.1
TEF		pg		4.2		pg	0.87
MAX TEF		"		<4.7		"	<2.3
ΣT4CDF	0.09	pg	2.4	4	0.33	pg	3.8
ΣP5CDF	0.21	"	2.3	2	0.22	"	0.82
ΣH6CDF	0.67	"	14	3	0.67	"	0.96
ΣH7CDF	0.68	"	6.4	1	1.6	"	<1.6
OCDF	0.27	"	5.7	1	0.5	"	11
ΣT4CDD	0.19	"	1.1	1	0.34	"	4.4
ΣP5CDD	0.14	"	0.89	1	0.93	"	2.6
ΣH6CDD	0.25	"	4.5	2	0.41	"	<0.41
ΣH7CDD	0.24	"	0.46	1	0.87	"	1.9
OCDD	0.24	"	9.3	1	0.63	"	9.1
Surrogate Recoveries	%					%	
2,3,7,8-T4CDF-13C12			92				98
2,3,7,8-T4CDD-13C12			78				79
1,2,3,7,8-P5CDF-13C12			73				74
1,2,3,7,8-P5CDD-13C12			64				65
1,2,3,6,7,8-H6CDF-13C12			25				76
1,2,3,6,7,8-H6CDD-13C12			56				83
1,2,3,4,6,7,8-H7CDF-13C12			22				48
1,2,3,4,6,7,8-H7CDD-13C12			69				67
OCDD-13C12			61				49

NYC 9/11 Public Portal Document

CONFIDENTIAL, CITY_21MC100_003483992

R02100400	R02100400R02100400R02100400	R02100400
02A	Client ID: 03A 03A 03A	Client ID: 04A
039047 02	Lab No.: 039048 02 039048 02 039048 02	Lab No.: 039049 02
02/10/09	Date Sampled: 02/10/09 02/10/09 02/10/09	Date Sampled: 02/10/09
	Matrix:	Matrix:

Component of Isomer	RDL	Units	TEF	% of Isomer	RDL	Units
2,3,7,8-Cl4DBF	0.13	pg	5.4	0.54	0.21	pg
2,3,7,8-Cl4DBD	0.18	"	1.8	1.8	0.13	"
1,2,3,7,8-Cl5DBF	0.13	"	1.5	0.074	0.89	"
2,3,4,7,8-Cl5DBF	0.12	"	1.7	0.84	0.79	"
1,2,3,7,8-Cl5DBD	0.27	"	0.44	0.22	0.33	"
1,2,3,4,7,8-Cl6DBF	0.15	"	<0.15	<0.015	0.23	"
1,2,3,6,7,8-Cl6DBF	1.5	"	<1.5	<0.15	0.71	"
2,3,4,6,7,8-Cl6DBF	0.17	"	2.2	0.22	0.26	"
1,2,3,7,8,9-Cl6DBF	0.19	"	0.32	0.032	0.29	"
1,2,3,4,7,8-Cl6DBD	0.19	"	<0.19	<0.019	0.21	"
1,2,3,6,7,8-Cl6DBD	0.58	"	<0.58	<0.058	0.20	"
1,2,3,7,8,9-Cl6DBD	0.13	"	0.95	0.095	0.2	"
1,2,3,4,6,7,8-Cl7DBF	11	"	<11	<0.11	11	"
1,2,3,4,7,8,9-Cl7DBF	13	"	<13	<0.13	140	"
1,2,3,4,6,7,8-Cl7DBD	0.16	"	3.2	0.032	0.11	"
1,2,3,4,6,7,8,9-Cl8DBF	0.78	"	<0.78	<0.00078	1.1	"
1,2,3,4,6,7,8,9-Cl8DBD	0.19	"	16	0.016	0.2	"
TEF		pg		3.8		pg
MAX TEF		"		<4.3		"
ΣT4CDF	2	pg	13		7	pg
ΣP5CDF	1	"	5.9		6	"
ΣH6CDF	1	"	2.5		2	"
ΣH7CDF	0	"	<13		0	"
OCDF	1	"	<0.78		0	"
ΣT4CDD	2	"	7.1		5	"
ΣP5CDD	1	"	9.3		8	"
ΣH6CDD	0	"	9.9		4	"
ΣH7CDD	1	"	7.2		2	"
OCDD	1	"	16		1	"
Surrogate Recoveries		%				%
2,3,7,8-T4CDF-13C12			159			71
2,3,7,8-T4CDD-13C12			133			93
1,2,3,7,8-P5CDF-13C12			161			112
1,2,3,7,8-P5CDD-13C12			166			107
1,2,3,6,7,8-H6CDF-13C12			49			30
1,2,3,6,7,8-H6CDD-13C12			75			73
1,2,3,4,6,7,8-H7CDF-13C12			37			13
1,2,3,4,6,7,8-H7CDD-13C12			95			85
OCDD-13C12			77			76

CONFIDENTIAL, CITY_21MC100_003483992

CONFIDENTIAL, CITY_21MC100_003483993

R02100400R02100400
04A 04A
039049 02 039049 02
02/10/09 02/10/09

R02100400R02100400R02100400R02100400
Client ID: 05A 05A 05A
Lab No.: 039050 02 039050 02 039050 02
Date Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

Client ID:
Lab No.:
Date Sampled:
Matrix:

Component	TEF	% of Isomer	RDL	Units	TEF	% of Isomer	RDL	Units
2,3,7,8-Cl4DBD	0.50		0.33	pg	1.8		0.13	pg
2,3,7,8-Cl4DBD	1.6		0.13	"	<0.13		1.4	"
1,2,3,7,8-Cl5DBD	0.45		0.36	"	<0.36		0.21	"
2,3,4,7,8-Cl5DBD	0.39		0.2	"	0.35		0.2	"
1,2,3,7,8-Cl5DBD	0.17		0.66	"	<0.66		0.89	"
1,2,3,4,7,8-Cl6DBD	0.32		0.31	"	<0.31		0.12	"
1,2,3,6,7,8-Cl6DBD	0.71		0.31	"	<0.31		0.12	"
2,3,4,6,7,8-Cl6DBD	0.37		0.35	"	0.42		0.13	"
1,2,3,7,8,9-Cl6DBD	0.29		0.39	"	<0.39		0.39	"
1,2,3,4,7,8-Cl6DBD	0.21		0.21	"	<0.21		0.16	"
1,2,3,6,7,8-Cl6DBD	0.20		0.20	"	<0.20		0.75	"
1,2,3,7,8,9-Cl6DBD	0.089		0.20	"	<0.20		0.15	"
1,2,3,4,6,7,8-Cl7DBD	0.36		89	"	<89		9.0	"
1,2,3,4,7,8,9-Cl7DBD	0.36		36	"	<36		17	"
1,2,3,4,6,7,8-Cl7DBD	0.53		0.53	"	<0.0053		0.14	"
1,2,3,4,6,7,8,9-Cl8DBD	0.0056		5.6	"	<5.6		1.1	"
1,2,3,4,6,7,8,9-Cl8DBD	0.0027		0.3	"	2.7		0.47	"
TEF	2.5			pg	0.40			pg
MAX TEF	<4.7			"	<2.3			"
ΣT4CDF	9	0.33	pg	3.6	4	0.13	pg	
ΣP5CDF	5	0.21	"	0.35	1	0.21	"	
ΣH6CDF	2	0.35	"	0.42	1	0.12	"	
ΣH7CDF	0	99	"	<99	0	25	"	
OCDF	0	5.6	"	<5.6	0	1.1	"	
ΣT4CDD	9	0.13	"	0.90	2	0.25	"	
ΣP5CDD	4	0.66	"	0.69	1	0.89	"	
ΣH6CDD	2	0.21	"	<0.21	0	0.15	"	
ΣH7CDD	2	0.19	"	<0.19	0	0.14	"	
OCDD	1	0.3	"	2.7	1	0.47	"	
Surrogate Recoveries			%				%	
2,3,7,8-T4CDF-13C12				134				
2,3,7,8-T4CDD-13C12				129				
1,2,3,7,8-P5CDF-13C12				120				
1,2,3,7,8-P5CDD-13C12				114				
1,2,3,6,7,8-H6CDF-13C12				50				
1,2,3,6,7,8-H6CDD-13C12				91				
1,2,3,4,6,7,8-H7CDF-13C12				29				
1,2,3,4,6,7,8-H7CDD-13C12				98				
OCDD-13C12				92				

CONFIDENTIAL, CITY_21MC100_003483993

City of New York, Department of Environmental Protection, Office of Environmental Health Assessment, 120 Broadway, New York, NY 10038

R02100400R02100400R02100400
06A 06A 06A
039051 02 039051 02 039051 02
02/10/09 02/10/09 02/10/09

R02100400R02100400R02100400
Client ID: 07A 07A 07A
Lab No.: 039052 02 039052 02 039052 02
Date Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

Component	TEF	# of Isomer	RDL	Units	TEF	# of Isomer	RDL
2,3,7,8-Cl ₄ DBF	0.79		0.13	pg	2.1	0.21	1.6
2,3,7,8-Cl ₄ DBF	<1.4		0.48	"	<0.48	<0.48	0.36
1,2,3,7,8-Cl ₅ DBF	0.076		0.26	"	0.69	0.035	0.32
2,3,4,7,8-Cl ₅ DBF	1.1		0.25	"	0.55	0.28	0.31
1,2,3,7,8-Cl ₅ DBF	0.33		1.2	"	<1.2	<0.61	0.41
1,2,3,4,7,8-Cl ₆ DBF	0.14		0.66	"	<0.66	<0.066	0.55
1,2,3,6,7,8-Cl ₆ DBF	0.11		0.28	"	0.82	0.082	0.55
2,3,4,6,7,8-Cl ₆ DBF	0.16		0.32	"	0.70	0.070	0.63
1,2,3,7,8,9-Cl ₆ DBF	<0.039		0.36	"	<0.36	<0.036	0.70
1,2,3,4,7,8-Cl ₆ DBF	0.075		0.18	"	<0.18	<0.018	0.45
1,2,3,6,7,8-Cl ₆ DBF	<0.075		0.17	"	<0.17	<0.017	0.43
1,2,3,7,8,9-Cl ₆ DBD	0.11		0.42	"	<0.42	<0.042	0.42
1,2,3,4,6,7,8-Cl ₇ DBF	<0.090		22	"	<22	<0.22	16
1,2,3,4,7,8,9-Cl ₇ DBF	<0.17		19	"	<19	<0.19	18
1,2,3,4,6,7,8-Cl ₇ DBD	0.026		0.31	"	1.3	0.013	1.3
1,2,3,4,6,7,8,9-Cl ₈ DBF	0.0019		0.25	"	6.3	0.0063	1.1
1,2,3,4,6,7,8,9-Cl ₈ DBD	0.011		0.4	"	8.7	0.0087	3.9
TEF	2.9			pg	0.70		
MAX TEF	<4.7			"	<2.4		
ΣT4CDF	23	10	0.13	pg	4.4	5	0.27
ΣP5CDF	12	7	0.26	"	1.8	3	0.32
ΣH6CDF	4.1	3	0.32	"	1.9	3	0.63
ΣH7CDF	<25	0	20	"	<20	0	17
OCDF	1.9	1	0.25	"	6.3	1	1.1
ΣT4CDD	12	7	0.22	"	0.43	1	0.36
ΣP5CDD	12	4	1	"	1.3	2	0.41
ΣH6CDD	13	6	0.17	"	<0.17	0	0.45
ΣH7CDD	2.6	1	0.31	"	2.6	2	1.3
OCDD	11	1	0.4	"	8.7	1	3.9
Surrogate Recoveries				%			
2,3,7,8-T4CDF-13C12					108		
2,3,7,8-T4CDD-13C12					95		
1,2,3,7,8-P5CDF-13C12					105		
1,2,3,7,8-P5CDD-13C12					111		
1,2,3,6,7,8-H6CDF-13C12					70		
1,2,3,6,7,8-H6CDD-13C12					89		
1,2,3,4,6,7,8-H7CDF-13C12					60		
1,2,3,4,6,7,8-H7CDD-13C12					86		
OCDD-13C12	77				76		

City of New York, Department of Environmental Protection, Office of Environmental Health Assessment, 120 Broadway, New York, NY 10038

CONFIDENTIAL,

CITY_21MC100_003483994

SUBJECT TO PROTECTIVE ORDER NO. 2, SEPT. 2008

NYC 9/11 Public Portal Document

R02100400R02100400R02100400
Client ID: 08A 08A 08A
Lab No.: 039053 02 039053 02 039053 02
Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

R02100400R02100400R02100400
Client ID: 09A 09A 09A
Lab No.: 039054 02 039054 02 039054 02
Date Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

Component	Units	TEF	of Isomer	RDL	Units	TEF	of Isomer
2,3,7,8-Cl4DBFpg	<1.6	<0.16		0.32	pg	3.1	0.31
2,3,7,8-Cl4DBD "	<0.36	<0.36		0.78	"	<0.78	<0.78
1,2,3,7,8-Cl5DBF	0.65	0.033		0.31	"	<0.31	<0.015
2,3,4,7,8-Cl5DBF	<0.31	<0.16		0.24	"	0.69	0.35
1,2,3,7,8-Cl5DBD	<0.41	<0.20		0.81	"	<0.81	<0.41
1,2,3,4,7,8-Cl6DBF	<0.55	<0.055		1.0	"	<1.0	<0.10
1,2,3,6,7,8-Cl6DBF	<0.55	<0.055		1.0	"	<1.0	<0.10
2,3,4,6,7,8-Cl6DBF	<0.63	<0.063		1.2	"	<1.2	<0.12
1,2,3,7,8,9-Cl6DBF	<0.70	<0.070		1.3	"	<1.3	<0.13
1,2,3,4,7,8-Cl6DBD	<0.45	<0.045		0.53	"	<0.53	<0.053
1,2,3,6,7,8-Cl6DBD	<0.43	<0.043		0.50	"	<0.50	<0.050
1,2,3,7,8,9-Cl6DBD	<0.42	<0.042		0.49	"	<0.49	<0.049
1,2,3,4,6,7,8-Cl7DBF	<16	<0.16		14	"	<14	<0.14
1,2,3,4,7,8,9-Cl7DBF	<18	<0.18		1.4	"	<1.4	<0.014
1,2,3,4,6,7,8-Cl7DBD	<1.3	<0.013		1.0	"	2.5	0.025
1,2,3,4,6,7,8,9-Cl8DBF	<1.1	<0.0011		0.86	"	4.2	0.0042
1,2,3,4,6,7,8,9-Cl8DBD	<3.9	<0.0039		1.0	"	30	0.030
TEF	pg	0.033			pg	0.71	
MAX TEF	"	<1.6			"	<2.7	
ΣT4CDF	pg	<0.27	0	0.32	pg	6.8	5
ΣP5CDF	"	0.65	1	0.31	"	1.3	2
ΣH6CDF	"	<0.63	0	1.0	"	<1.0	0
ΣH7CDF	"	<17	0	16	"	<16	0
OCDF	"	<1.1	0	0.86	"	4.2	1
ΣT4CDD	"	<0.36	0	0.53	"	0.70	1
ΣP5CDD	"	0.63	1	0.81	"	<0.81	0
ΣH6CDD	"	<0.45	0	0.53	"	3.5	1
ΣH7CDD	"	<1.3	0	1.0	"	5.5	2
OCDD	"	<3.9	0	1.0	"	30	1
Surrogate Recoveries					%		
2,3,7,8-T4CDF-13C12	86					97	
2,3,7,8-T4CDD-13C12	82					77	
1,2,3,7,8-P5CDF-13C12	71					73	
1,2,3,7,8-P5CDD-13C12	65					64	
1,2,3,6,7,8-H6CDF-13C12	48					69	
1,2,3,6,7,8-H6CDD-13C12	75					80	
1,2,3,4,6,7,8-H7CDF-13C12	27					59	
1,2,3,4,6,7,8-H7CDD-13C12	22					76	
OCDD-13C12	67					52	

NYC 9/11 Public Portal Document

NYC 9/11 Public Portal Document

R02100400R02100400R02100400			R02100400R02100400		
Client ID:	10A	10A	Client ID:	11A	11A
Lab No.:	039055 02	039055 02	Lab No.:	039056 02	039056 02
Date Sampled:	02/10/09	02/10/09	Date Sampled:	02/10/09	02/10/09
Matrix:			Matrix:		

Component	RDL	Units	TEF	% of Isomer	RDL	Units	TEF
2,3,7,8-Cl4DBP	0.14	pg	1.7	0.17	1.8	pg	2.6
2,3,7,8-Cl4DBP	0.47	"	<0.47	<0.47	1.3	"	<1.3
1,2,3,7,8-Cl5DBP	0.14	"	0.72	0.036	2.0	"	<2.0
2,3,4,7,8-Cl5DBP	0.14	"	1.1	0.55	1.9	"	<1.9
1,2,3,7,8-Cl5DBP	0.54	"	<0.54	<0.27	2.2	"	<2.2
1,2,3,4,7,8-Cl6DBP	0.24	"	2.0	0.20	1.0	"	<1.0
1,2,3,6,7,8-Cl6DBP	0.24	"	<1.9	<0.19	1.0	"	<1.0
2,3,4,6,7,8-Cl6DBP	0.24	"	2.4	0.24	1.2	"	<1.2
1,2,3,7,8,9-Cl6DBP	0.24	"	<2.3	<0.23	1.3	"	<1.3
1,2,3,4,7,8-Cl6DBP	0.30	"	1.3	0.13	2.1	"	<2.1
1,2,3,6,7,8-Cl6DBP	0.29	"	1.4	0.14	2.0	"	<2.0
1,2,3,7,8,9-Cl6DBP	0.28	"	2.0	0.20	2.0	"	<2.0
1,2,3,4,6,7,8-Cl7DBP	0.24	"	<6.2	<0.062	1.8	"	<1.8
1,2,3,4,7,8,9-Cl7DBP	0.33	"	<3.3	<0.033	4.8	"	<4.8
1,2,3,4,6,7,8-Cl7DBP	0.28	"	1.9	0.019	2.7	"	<2.7
1,2,3,4,6,7,8,9-Cl8DBP	0.28	"	4.2	0.0042	2.8	"	<2.8
1,2,3,4,6,7,8,9-Cl8DBP	0.28	"	12	0.012	4.7	"	5.0
TEF		pg		1.7		pg	0.27
MAX TEF		"		<3.0		"	<4.9
ΣT4CDF	0.14	pg	2.5	2	1.8	pg	2.6
ΣP5CDF	0.14	"	3.8	6	2.0	"	<2.0
ΣH6CDF	0.24	"	7.3	5	1.2	"	<1.2
ΣH7CDF	26	"	<26	0	2.0	"	<2.0
OCDF	0.98	"	4.2	1	2.8	"	<2.8
ΣT4CDD	0.13	"	1.7	3	1.3	"	<1.3
ΣP5CDD	0.60	"	<0.60	0	2.2	"	<2.2
ΣH6CDD	0.31	"	6.2	5	2.1	"	<2.1
ΣH7CDD	0.34	"	3.8	2	2.7	"	<2.7
OCDD	0.66	"	12	1	4.7	"	5.0
Surrogate Recoveries	%					%	
2,3,7,8-T4CDF-13C12			110				91
2,3,7,8-T4CDD-13C12			85				85
1,2,3,7,8-P5CDF-13C12			77				58
1,2,3,7,8-P5CDD-13C12			60				65
1,2,3,6,7,8-H6CDF-13C12			59				89
1,2,3,6,7,8-H6CDD-13C12			80				69
1,2,3,4,6,7,8-H7CDF-13C12			51				61
1,2,3,4,6,7,8-H7CDD-13C12			90				64
OCDD-13C12			73				93

NYC 9/11 Public Portal Document

CONFIDENTIAL, CITY_21MC100_003483997

R02100400	R02100400R02100400R02100400	R02100400
11A	Client ID: 12A 12A 12A	Client ID: 13A
039056 02	Lab No.: 039057 02 039057 02 039057 02	Lab No.: 039058 02
02/10/09	Date Sampled: 02/10/09 02/10/09 02/10/09	Date Sampled: 02/10/09
	Matrix:	Matrix:

Component of Isomer	RDL	Units	TEF	% of Isomer	RDL	Units
2,3,7,8-Cl4DBF	1.2	pg	<1.2	<0.12	1.3	pg
2,3,7,8-Cl4DBD	3.1	"	<3.1	<3.1	1.1	"
1,2,3,7,8-Cl5DBF	2.3	"	<2.3	<0.11	0.99	"
2,3,4,7,8-Cl5DBF	2.2	"	<2.2	<1.1	0.96	"
1,2,3,7,8-Cl5DBD	2.5	"	<2.5	<1.3	3.8	"
1,2,3,4,7,8-Cl6DBF	2.6	"	<2.6	<0.26	1.5	"
1,2,3,6,7,8-Cl6DBF	16	"	<16	<1.6	1.4	"
2,3,4,6,7,8-Cl6DBF	80	"	<80	<8.0	1.6	"
1,2,3,7,8,9-Cl6DBF	3.2	"	<3.2	<0.32	1.8	"
1,2,3,4,7,8-Cl6DBD	61	"	<61	<6.1	0.59	"
1,2,3,6,7,8-Cl6DBD	6.0	"	<6.0	<0.60	0.56	"
1,2,3,7,8,9-Cl6DBD	5.9	"	<5.9	<0.59	0.54	"
1,2,3,4,6,7,8-Cl7DBF	5.6	"	<5.6	<0.056	5.2	"
1,2,3,4,7,8,9-Cl7DBF	6.4	"	<6.4	<0.064	6.0	"
1,2,3,4,6,7,8-Cl7DBD	3.5	"	<3.5	<0.035	1.2	"
1,2,3,4,6,7,8,9-Cl8DBF	3.2	"	5.4	0.0054	1.3	"
1,2,3,4,6,7,8,9-Cl8DBD	3.0	"	<3.0	<0.030	0.85	"
TEF		pg		0.0054		pg
MAX TEF		"		<23		"
ΣT4CDF	1	1.2	pg	<1.2	0	1.3
ΣP5CDF	0	2.3	"	<2.3	0	0.99
ΣH6CDF	0	2.6	"	<2.6	0	1.5
ΣH7CDF	0	6.2	"	<6.2	0	5.8
OCDF	0	3.2	"	5.4	1	1.3
ΣT4CDD	0	3.1	"	<3.1	0	1.1
ΣP5CDD	0	2.5	"	<2.5	0	3.8
ΣH6CDD	0	290	"	<290	0	0.56
ΣH7CDD	0	3.5	"	<3.5	0	1.2
OCDD	1	3.0	"	<3.0	0	0.85
Surrogate Recoveries		%				%
2,3,7,8-T4CDF-13C12			76			80
2,3,7,8-T4CDD-13C12			84			83
1,2,3,7,8-P5CDF-13C12			51			69
1,2,3,7,8-P5CDD-13C12			46			67
1,2,3,6,7,8-H6CDF-13C12			68			77
1,2,3,6,7,8-H6CDD-13C12			69			90
1,2,3,4,6,7,8-H7CDF-13C12			60			88
1,2,3,4,6,7,8-H7CDD-13C12			61			99
OCDD-13C12			117			94

CONFIDENTIAL, CITY_21MC100_003483997

NYC 9/11 Public Portal Document

R02100400R02100400
13A 13A
039058 02 039058 02
02/10/09 02/10/09

R02100400R02100400R02100400R02100400
Client ID: 14A 14A 14A
Lab No.: 039059 02 039059 02 039059 02
Date Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

Client ID:
Lab No.:
Date Sampled:
Matrix:

Component	TEF	% of Isomer	RDL	Units	TEF	% of Isomer	RDL	Units
2,3,7,8-Cl ₄ DBF0.13			1.1	pg	<1.1		1.0	pg
2,3,7,8-Cl ₄ DBF1.1			1.1	"	<1.1		2.0	"
1,2,3,7,8-Cl ₅ DBF0.50			1.2	"	<1.2		1.7	"
2,3,4,7,8-Cl ₅ DBF48			1.2	"	<1.2		1.7	"
1,2,3,7,8-Cl ₅ DBF9			1.4	"	<1.4		1.5	"
1,2,3,4,7,8-Cl ₆ DBF5			1.0	"	<1.0		1.4	"
1,2,3,6,7,8-Cl ₆ DBF4			1.0	"	<1.0		1.4	"
2,3,4,6,7,8-Cl ₆ DBF6			1.1	"	<1.1		1.6	"
1,2,3,7,8,9-Cl ₆ DBF8			1.3	"	<1.3		1.7	"
1,2,3,4,7,8-Cl ₆ DBF59			1.2	"	<1.2		1.3	"
1,2,3,6,7,8-Cl ₆ DBF56			1.1	"	<1.1		1.3	"
1,2,3,7,8,9-Cl ₆ DBF4			1.1	"	<1.1		1.2	"
1,2,3,4,6,7,8-Cl ₇ DBF			1.2	"	<1.2		2.8	"
1,2,3,4,7,8,9-Cl ₇ DBF			1.4	"	<1.4		3.2	"
1,2,3,4,6,7,8-Cl ₇ DBF			1.2	"	<1.2		1.4	"
1,2,3,4,6,7,8,9-Cl ₈ DBF			2.1	"	<2.1		1.6	"
1,2,3,4,6,7,8,9-Cl ₈ DBF			4.3	"	<4.3		1.9	"
TEF	0.0045			pg	0			pg
MAX TEF	<4.6			"	<3.4			"
ΣT4CDF	0	1.1	pg	<1.1	0	1.0	pg	
ΣP5CDF	0	1.2	"	<1.2	0	1.7	"	
ΣH6CDF	0	1.0	"	<1.0	0	1.6	"	
ΣH7CDF	0	1.4	"	<1.4	0	3.1	"	
OCDF	0	2.1	"	<2.1	0	1.6	"	
ΣT4CDD	1	1.1	"	<1.1	0	2.0	"	
ΣP5CDD	0	1.4	"	<1.4	0	1.5	"	
ΣH6CDD	0	1.1	"	<1.1	0	1.3	"	
ΣH7CDD	0	1.2	"	<1.2	0	1.4	"	
OCDD	1	4.3	"	<4.3	0	1.9	"	
Surrogate Recoveries			%				%	
2,3,7,8-T4CDF-13C12				84				
2,3,7,8-T4CDD-13C12				85				
1,2,3,7,8-P5CDF-13C12				70				
1,2,3,7,8-P5CDD-13C12				79				
1,2,3,6,7,8-H6CDF-13C12				77				
1,2,3,6,7,8-H6CDD-13C12				90				
1,2,3,4,6,7,8-H7CDF-13C12				87				
1,2,3,4,6,7,8-H7CDD-13C12				98				
OCDD-13C12				87				

NYC 9/11 Public Portal Document

CONFIDENTIAL,

CITY_21MC100_003483998

SUBJECT TO PROTECTIVE ORDER NO. 2, SEPT. 2008

CONFIDENTIAL, CITY_21MC100_003483999

R02100400R02100400R02100400
15A 15A 15A
039060 02 039060 02 039060 02
02/10/09 02/10/09 02/10/09

R02100400R02100400R02100400
Client ID: 16A 16A 16A
Lab No.: 039061 02 039061 02 039061 02
Date Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

Component	TEF	# of Isomer	RDL	Units	TEF	# of Isomer	RDL
2,3,7,8-Cl4DBF	1.9		12	pg	<12		0.89
2,3,7,8-Cl4DBD	<2.0		1.4	"	13		1.5
1,2,3,7,8-Cl5DBF	<0.087		1.1	"	<1.1		1.2
2,3,4,7,8-Cl5DBF	<0.84		1.1	"	2.3		1.2
1,2,3,7,8-Cl5DBD	<0.77		1.2	"	<1.2		1.9
1,2,3,4,7,8-Cl6DBF	<0.14		3.5	"	<3.5		1.1
1,2,3,6,7,8-Cl6DBF	<0.14		1.4	"	<1.4		1.1
2,3,4,6,7,8-Cl6DBF	<0.16		1.6	"	<1.6		1.3
1,2,3,7,8,9-Cl6DBF	<0.17		1.8	"	<1.8		1.4
1,2,3,4,7,8-Cl6DBD	<0.13		1.3	"	<1.3		2.5
1,2,3,6,7,8-Cl6DBD	<0.13		1.2	"	<1.2		2.4
1,2,3,7,8,9-Cl6DBD	<0.12		1.2	"	<1.2		2.3
1,2,3,4,6,7,8-Cl7DBF	<0.028		1.6	"	<1.6		2.7
1,2,3,4,7,8,9-Cl7DBF	<0.032		1.9	"	<1.9		3.1
1,2,3,4,6,7,8-Cl7DBD	<0.014		2.0	"	12		1.4
1,2,3,4,6,7,8,9-Cl8DBF	0.0020		5.4	"	<5.4		3.4
1,2,3,4,6,7,8,9-Cl8DBD	0.011		1.7	"	110		5.4
TEF	0.21			pg	15		
MAX TEF	<4.9			"	<18		
ΣT4CDF	1.9	1	0.82	pg	16	4	0.89
ΣP5CDF	<1.7	0	1.1	"	11	4	1.2
ΣH6CDF	<1.6	0	1.4	"	<1.4	0	1.3
ΣH7CDF	<3.1	0	1.8	"	<1.8	0	3.0
OCDF	2.0	1	5.4	"	<5.4	0	3.4
ΣT4CDD	<2.0	0	1.4	"	58	5	1.5
ΣP5CDD	<1.5	0	1.2	"	21	3	1.9
ΣH6CDD	<1.3	0	1.2	"	22	2	2.5
ΣH7CDD	<1.4	0	2.0	"	25	2	1.4
OCDD	11	1	1.7	"	110	1	5.4
Surrogate Recoveries				%			
2,3,7,8-T4CDF-13C12					74		
2,3,7,8-T4CDD-13C12					40		
1,2,3,7,8-P5CDF-13C12					64		
1,2,3,7,8-P5CDD-13C12					68		
1,2,3,6,7,8-H6CDF-13C12					54		
1,2,3,6,7,8-H6CDD-13C12					70		
1,2,3,4,6,7,8-H7CDF-13C12					49		
1,2,3,4,6,7,8-H7CDD-13C12					78		
OCDD-13C12	182				105		

CONFIDENTIAL, CITY_21MC100_003483999

NYC 9/11 Public Portal Document

R02100400R02100400R02100400
Client ID: 17A 17A 17A
Lab No.: 039062 02 039062 02 039062 02
Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

R02100400R02100400R02100400
Client ID: 18A 18A 18A
Lab No.: 039063 02 039063 02 039063 02
Date Sampled: 02/10/09 02/10/09 02/10/09
Matrix:

Component	Units	TEF	of Isomer	RDL	Units	TEF	of Isomer
2,3,7,8-Cl4DBFpg	<0.89	<0.089		4.7	pg	<4.7	<0.47
2,3,7,8-Cl4DBD "	<1.5	<1.5		0.72	"	<0.72	<0.72
1,2,3,7,8-Cl5DBF	<1.2	<0.060		0.40	"	<0.40	<0.020
2,3,4,7,8-Cl5DBF	<1.2	<0.58		0.36	"	1.2	0.58
1,2,3,7,8-Cl5DBD	<1.9	<0.96		1.1	"	<1.1	<0.55
1,2,3,4,7,8-Cl6DBF	<1.1	<0.11		1.9	"	<1.9	<0.19
1,2,3,6,7,8-Cl6DBF	<1.1	<0.11		1.5	"	<1.5	<0.15
2,3,4,6,7,8-Cl6DBF	<1.3	<0.13		2.3	"	<2.3	<0.23
1,2,3,7,8,9-Cl6DBF	<1.4	<0.14		0.64	"	2.2	0.22
1,2,3,4,7,8-Cl6DBD	<2.5	<0.25		0.81	"	<0.81	<0.081
1,2,3,6,7,8-Cl6DBD	<2.4	<0.24		1.7	"	<1.7	<0.17
1,2,3,7,8,9-Cl6DBD	<2.3	<0.23		0.73	"	2.3	0.23
1,2,3,4,6,7,8-Cl7DBF	<2.7	<0.027		3.7	"	<3.7	<0.037
1,2,3,4,7,8,9-Cl7DBF	<3.1	<0.031		2.7	"	<2.7	<0.027
1,2,3,4,6,7,8-Cl7DBD	<1.4	<0.014		4.4	"	<4.4	<0.044
1,2,3,4,6,7,8,9-Cl8DBF	<3.4	<0.0034		1.4	"	11	0.011
1,2,3,4,6,7,8,9-Cl8DBD	<5.4	<0.0054		2.8	"	22	0.022
TEF	pg	0			pg	1.1	
MAX TEF	"	<4.5			"	<3.7	
ΣT4CDF	pg	<0.89	0	0.27	pg	11	9
ΣP5CDF	"	<1.2	0	0.4	"	2.7	2
ΣH6CDF	"	<1.3	0	0.59	"	2.2	1
ΣH7CDF	"	<3.0	0	5.9	"	<5.9	0
OCDF	"	<3.4	0	1.4	"	11	1
ΣT4CDD	"	<1.5	0	0.47	"	23	3
ΣP5CDD	"	<1.9	0	1.1	"	3.3	1
ΣH6CDD	"	<2.5	0	0.75	"	2.3	1
ΣH7CDD	"	<1.4	0	0.20	"	<0.20	0
OCDD	"	<5.4	0	2.8	"	22	1
Surrogate Recoveries					%		
2,3,7,8-T4CDF-13C12	69					94	
2,3,7,8-T4CDD-13C12	73					85	
1,2,3,7,8-P5CDF-13C12	49					79	
1,2,3,7,8-P5CDD-13C12	51					68	
1,2,3,6,7,8-H6CDF-13C12	75					95	
1,2,3,6,7,8-H6CDD-13C12	80					71	
1,2,3,4,6,7,8-H7CDF-13C12	87					81	
1,2,3,4,6,7,8-H7CDD-13C12	71					67	
OCDD-13C12	50					47	

NYC 9/11 Public Portal Document

NYC 9/11 Public Portal Document

R02100400
20A
039065 02
02/10/09

Component of Isomers

2,3,7,8-Cl4DBF
2,3,7,8-Cl4DBD
1,2,3,7,8-Cl5DBF
2,3,4,7,8-Cl5DBF
1,2,3,7,8-Cl5DBD
1,2,3,4,7,8-Cl6DBF
1,2,3,6,7,8-Cl6DBF
2,3,4,6,7,8-Cl6DBF
1,2,3,7,8,9-Cl6DBF
1,2,3,4,7,8-Cl6DBD
1,2,3,6,7,8-Cl6DBD
1,2,3,7,8,9-Cl6DBD
1,2,3,4,6,7,8-Cl7DBF
1,2,3,4,7,8,9-Cl7DBF
1,2,3,4,6,7,8-Cl7DBD
1,2,3,4,6,7,8,9-Cl8DBF
1,2,3,4,6,7,8,9-Cl8DBD

TEF
MAX TEF

ΣT4CDF	1
ΣP5CDF	0
ΣH6CDF	0
ΣH7CDF	0
OCDF	1
ΣT4CDD	0
ΣP5CDD	0
ΣH6CDD	0
ΣH7CDD	0
OCDD	0

Surrogate Recoveries

2,3,7,8-T4CDF-13C12
2,3,7,8-T4CDD-13C12
1,2,3,7,8-P5CDF-13C12
1,2,3,7,8-P5CDD-13C12
1,2,3,6,7,8-H6CDF-13C12
1,2,3,6,7,8-H6CDD-13C12
1,2,3,4,6,7,8-H7CDF-13C12
1,2,3,4,6,7,8-H7CDD-13C12
OCDD-13C12

NYC 9/11 Public Portal Document

CONFIDENTIAL,
SUBJECT TO PROTECTIVE ORDER NO. 2, SEPT. 2008

CITY_21MC100_003484002

CONFIDENTIAL, CITY_21MC100_003484003

Component	RDL	Units	BLANK	TEF	% of Isomer	MR	RDL	Units	BLANK
Batch Code:			1016JM01						1021NZ01
2,3,7,8-Cl4DBD	0.11	pg	1.1	0.11		100%	0.85	pg	<0.85
2,3,7,8-Cl4DBD	0.22	"	0.53	0.53		118%	0.89	"	<0.89
1,2,3,7,8-Cl5DBF	0.36	"	<0.36	<0.018		109%	0.98	"	<0.98
2,3,4,7,8-Cl5DBF	0.40	"	<0.40	<0.20		92%	0.94	"	<0.94
1,2,3,7,8-Cl5DBF	0.31	"	<0.31	<0.15		92%	0.81	"	<0.81
1,2,3,4,7,8-Cl6DBF	0.35	"	0.58	0.058		90%	0.75	"	<0.75
1,2,3,6,7,8-Cl6DBF	0.37	"	<0.47	<0.047		97%	0.75	"	<0.75
2,3,4,6,7,8-Cl6DBF	0.55	"	1.0	0.10		162%	0.85	"	<0.85
1,2,3,7,8,9-Cl6DBF	0.55	"	<0.76	<0.076		162%	0.94	"	<0.94
1,2,3,4,7,8-Cl6DBD	0.30	"	<0.30	<0.030		84%	1.3	"	<1.3
1,2,3,6,7,8-Cl6DBD	0.38	"	<0.28	<0.028		92%	1.3	"	<1.3
1,2,3,7,8,9-Cl6DBD	0.30	"	<1.0	<0.10		104%	1.2	"	<1.2
1,2,3,4,6,7,8-Cl7DBF	0.25	"	<2.5	<0.025		101%	2.4	"	<2.4
1,2,3,4,7,8,9-Cl7DBF	0.25	"	<2.8	<0.028		179%	2.8	"	<2.8
1,2,3,4,6,7,8-Cl7DBD	0.25	"	<1.6	<0.016		97%	2.3	"	<2.3
1,2,3,4,6,7,8,9-Cl8DBF	0.25	"	4.6	0.0046		75%	1.2	"	1.6
1,2,3,4,6,7,8,9-Cl8DBD	0.25	"	9.5	0.0095		95%	3.4	"	5.5
FET		pg		0.825				pg	
FET MAX		"		<1.5				"	
ΣT4CDF	0.11	pg	2.2		5	100%	0.40	pg	<0.40
ΣP5CDF	0.18	"	<0.18		0	101%	0.98	"	<0.98
ΣH6CDF	0.38	"	1.6		2	128%	0.75	"	<0.75
ΣH7CDF	1.7	"	0.26		1	140%	2.7	"	<2.7
OCDF	0.26	"	4.6		1	75%	1.2	"	1.6
ΣT4CDD	0.14	"	0.53		1	118%	0.89	"	<0.89
ΣP5CDD	0.45	"	<0.45		0	92%	0.81	"	<0.81
ΣH6CDD	0.30	"	<0.30		0	93%	1.3	"	<1.3
ΣH7CDD	0.47	"	<0.47		1	97%	2.3	"	<2.3
OCDD	0.27	"	9.5		1	95%	3.4	"	5.5
Surrogate Recoveries		%						%	
2,3,7,8-T4CDF-13C12			101						67
2,3,7,8-T4CDD-13C12			82						65
1,2,3,7,8-P5CDF-13C12			86						45
1,2,3,7,8-P5CDD-13C12			75						44
1,2,3,6,7,8-H6CDF-13C12			47						68
1,2,3,6,7,8-H6CDD-13C12			72						77
1,2,3,4,6,7,8-H7CDF-13C12			36						51
1,2,3,4,6,7,8-H7CDD-13C12			82						65
OCDD-13C12			75						131

CONFIDENTIAL, CITY_21MC100_003484003

CONFIDENTIAL,

CITY_21MC100_003484003

SUBJECT TO PROTECTIVE ORDER NO. 2, SEPT. 2008

CONFIDENTIAL, CITY_21MC100_003484004

Component	Batch Code:	TEF	of Isomer	MR	RDL	Units	BLANK	TEF	of Isomer	MR
							1025NZ01			
2,3,7,8-Cl4DBF	0.085			90%	0.47	pg	1.3	0.13		97%
2,3,7,8-Cl4DBF	0.89			98%	0.47	"	0.86	0.86		108%
1,2,3,7,8-Cl5DBF	0.49			100%	0.56	"	<0.56	<0.028		107%
2,3,4,7,8-Cl5DBF	0.47			92%	0.54	"	<0.54	<0.27		94%
1,2,3,7,8-Cl5DBF	0.40			81%	1.1	"	<1.1	<0.54		89%
1,2,3,4,7,8-Cl6DBF	0.75			87%	0.32	"	<0.32	<0.032		102%
1,2,3,6,7,8-Cl6DBF	0.75			89%	0.30	"	<0.30	<0.030		98%
2,3,4,6,7,8-Cl6DBF	0.85			77%	0.35	"	<0.35	<0.035		104%
1,2,3,7,8,9-Cl6DBF	0.94			73%	0.38	"	<0.38	<0.038		103%
1,2,3,4,7,8-Cl6DBF	0.83			84%	0.80	"	<0.80	<0.080		100%
1,2,3,6,7,8-Cl6DBF	0.83			80%	0.75	"	<0.75	<0.075		92%
1,2,3,7,8,9-Cl6DBF	0.82			82%	0.73	"	<0.73	<0.073		93%
1,2,3,4,6,7,8-Cl7DBF	0.72			96%	0.72	"	<0.72	<0.0072		101%
1,2,3,4,7,8,9-Cl7DBF	0.72			89%	1.1	"	<1.1	<0.011		95%
1,2,3,4,6,7,8-Cl7DBF	0.72			92%	5.8	"	<5.8	<0.058		98%
1,2,3,4,6,7,8,9-Cl8DBF	0.85			76%	5.9	"	2.7	0.0027		95%
1,2,3,4,6,7,8,9-Cl8DBF	0.85			89%	4.0	"	11	0.011		98%
FET	0.007					pg		1.0		
FET MAX	<2.7					"		<2.3		
ΣT4CDF	0		90%	0.47	pg		1.3		1	97%
ΣP5CDF	0		96%	0.56	"		<0.56		0	101%
ΣH6CDF	0		82%	0.35	"		<0.35		0	102%
ΣH7CDF	0		93%	0.81	"		<0.81		0	98%
OCDF	1		76%	5.9	"		2.7		1	95%
ΣT4CDD	0		98%	0.47	"		0.86		1	108%
ΣP5CDD	0		81%	1.1	"		<1.1		0	89%
ΣH6CDD	0		82%	0.75	"		<0.75		0	95%
ΣH7CDD	0		92%	0.95	"		<0.95		0	98%
OCDD	1		89%	4.0	"		11		1	98%
Surrogate Recoveries					%					
2,3,7,8-T4CDF-13C12							91			
2,3,7,8-T4CDD-13C12							82			
1,2,3,7,8-P5CDF-13C12							80			
1,2,3,7,8-P5CDD-13C12							74			
1,2,3,6,7,8-H6CDF-13C12							87			
1,2,3,6,7,8-H6CDD-13C12							85			
1,2,3,4,6,7,8-H7CDF-13C12							86			
1,2,3,4,6,7,8-H7CDD-13C12							37			
OCDD-13C12							68			

CONFIDENTIAL, CITY_21MC100_003484004

C"ARaia,gaas itaiaique"14PSC Aanaityticiaa

Batch Cod 1016JM01 1021NZ01 1025NZ01

2,3,7,8-Cl4 039046 02 039056 02 039063 02
 039047 02 039057 02 039064 02
 039048 02 039058 02 039065 02
 039049 02 039059 02
 039050 02 039060 02
 039051 02 039061 02
 039052 02 039062 02
 039053 02
 039054 02
 039055 02

Date Analy:10/30/200210/25/2002 11/2/2002
 Date Prepa10/16/200210/21/200210/25/2002

Batch Cod 1016JM01 1021NZ01 1025NZ01

ΣT4CDF et 039046 02 039056 02 039063 02
 039047 02 039057 02 039064 02
 039048 02 039058 02 039065 02
 039049 02 039059 02
 039050 02 039060 02
 039051 02 039061 02
 039052 02 039062 02
 039053 02
 039054 02
 039055 02

Date Analy:10/30/200210/25/2002 11/2/2002
 Date Prepa10/16/200210/21/200210/25/2002

L"ARaia,aitaiaic="Nso d e c e r t i f i c a t i o n
 n h C"ARaia,aita

CONFIDENTIAL,

CITY_21MC100_003484005

SUBJECT TO PROTECTIVE ORDER NO. 2, SEPT. 2008